daniel skovronsky. you for being with us today, and i want to ask you about this specific trial, but tell us first about the trials you've run already on this drug and anything you see so far that tells you about its safety and any efficacy signs >> thanks. it's a pleasure to be here we just started in patients just over two months ago, at the end of may, and we started in hospital situations just looking at the safety of the drug, and he with found it was well tolerated, no serious events or anything like that then we moved to diagnosed patients people who just got the diagnosis of covid-19 and are early in the disease course, so we're seeing if we can slow down the sickness in their body or keep them from getting too sick. we don't have data from this trial yet, we've just been watching the safety, which looks good we hope to get effects from that first ambulantory trial in the next month or two. >> when committee expect to get results from the hospitalized patients >> it was just a small number of pa